Literature DB >> 21851978

Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes.

Benjamin M Craig1, Dana E Rollison, Alan F List, Christopher R Cogle.   

Abstract

Considering current reliance on cancer registry data, we sought to assess the potential for bias in myelodysplastic syndrome (MDS) registration using SEER-Medicare data 2001-2005. Using a validated claims-based algorithm, we identified and compared registered and non-registered MDS patients, and found that median cumulative survival was 18 and 28 months, 74% and 64% used erythropoiesis-stimulating agents (ESAs), and average 6-month health care cost was $24,249 and $21,750, respectively. While most non-registered MDS patients showed resource utilization and survival characteristics consistent with lower-risk MDS, a subset was registered as acute myeloid leukemia (7.6%) and accounted for early mortality.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21851978      PMCID： PMC3191243          DOI： 10.1016/j.leukres.2011.07.028

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  10 in total

1.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Authors:  Joan L Warren; Carrie N Klabunde; Deborah Schrag; Peter B Bach; Gerald F Riley
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

2.  Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry.

Authors:  Judith Neukirchen; Wilma M Schoonen; Corinna Strupp; Norbert Gattermann; Carlo Aul; Rainer Haas; Ulrich Germing
Journal:  Leuk Res       Date:  2011-06-25       Impact factor: 3.156

3.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

Review 4.  Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries.

Authors:  Stuart L Goldberg; Er Chen; Mitra Corral; Amy Guo; Nikita Mody-Patel; Andrew L Pecora; Marianne Laouri
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

5.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

6.  Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries.

Authors:  Christopher R Cogle; Benjamin M Craig; Dana E Rollison; Alan F List
Journal:  Blood       Date:  2011-04-29       Impact factor: 22.113

7.  Efficacy of lenalidomide in myelodysplastic syndromes.

Authors:  Alan List; Sandy Kurtin; Denise J Roe; Andrew Buresh; Daruka Mahadevan; Deborah Fuchs; Lisa Rimsza; Ruth Heaton; Robert Knight; Jerome B Zeldis
Journal:  N Engl J Med       Date:  2005-02-10       Impact factor: 91.245

8.  Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.

Authors:  Milena Sant; Claudia Allemani; Carmen Tereanu; Roberta De Angelis; Riccardo Capocaccia; Otto Visser; Rafael Marcos-Gragera; Marc Maynadié; Arianna Simonetti; Jean-Michel Lutz; Franco Berrino
Journal:  Blood       Date:  2010-07-27       Impact factor: 22.113

9.  Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

Authors:  Dana E Rollison; Nadia Howlader; Martyn T Smith; Sara S Strom; William D Merritt; Lynn A Ries; Brenda K Edwards; Alan F List
Journal:  Blood       Date:  2008-04-28       Impact factor: 22.113

10.  Myelodysplastic syndromes: incidence and survival in the United States.

Authors:  Xiaomei Ma; Monique Does; Azra Raza; Susan T Mayne
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860
  10 in total
  6 in total

1.  Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults.

Authors:  Dan P Zandberg; Ting-Ying Huang; Xuehua Ke; Maria R Baer; Steven D Gore; Sheila Weiss Smith; Amy J Davidoff
Journal:  Haematologica       Date:  2012-11-09       Impact factor: 9.941

2.  Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.

Authors:  Jennifer E Vaughn; Megan Othus; Morgan A Powell; Kelda M Gardner; Donelle L Rizzuto; Paul C Hendrie; Pamela S Becker; Paul S Pottinger; Elihu H Estey; Roland B Walter
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

3.  Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.

Authors:  Melissa A Deadmond; Julie A Smith-Gagen
Journal:  J Cancer Res Clin Oncol       Date:  2015-05-13       Impact factor: 4.553

4.  Underreporting of myeloid malignancies by United States cancer registries.

Authors:  Benjamin M Craig; Dana E Rollison; Alan F List; Christopher R Cogle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-01-11       Impact factor: 4.254

5.  The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes.

Authors:  Rong Wang; Cary P Gross; Kevin Frick; Xiao Xu; Jessica Long; Azra Raza; Naomi Galili; Jennifer Zikria; Yongtao Guan; Xiaomei Ma
Journal:  Leuk Res       Date:  2012-08-20       Impact factor: 3.156

6.  Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects.

Authors:  Naoko I Simonds; Muin J Khoury; Sheri D Schully; Katrina Armstrong; Wendy F Cohn; David A Fenstermacher; Geoffrey S Ginsburg; Katrina A B Goddard; William A Knaus; Gary H Lyman; Scott D Ramsey; Jianfeng Xu; Andrew N Freedman
Journal:  J Natl Cancer Inst       Date:  2013-05-09       Impact factor: 13.506
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.